Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma

Clinics in Liver Disease

Volumn 19, Issue 2, 2015, Pages 361-379

  Noureddin, Mazen ^a   Rinella, Mary E ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemoprevention; Cirrhosis; Diabetes; Hepatocellular carcinoma; Insulin resistance; Nonalcoholic steatohepatitis; Noncirrhotic; Obesity

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; METFORMIN; S ADENOSYLMETHIONINE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; ANTIDIABETIC AGENT;

CANCER GROWTH; CANCER RISK; CHEMOPROPHYLAXIS; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; HUMAN; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; INCIDENCE; INFLAMMATION; LIVER NEOPLASMS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; DIABETES MELLITUS, TYPE 2; ENDOPLASMIC RETICULUM STRESS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEPTIN; LIVER NEOPLASMS; METFORMIN; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS; S-ADENOSYLMETHIONINE; TOLL-LIKE RECEPTORS;

EID: 84928825488     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.01.012     Document Type: Review

References (117)

1. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131.
2. Rinella M.E., Loomba R., Caldwell S.H., et al. Controversies in the diagnosis and management of NAFLD and NASH. Gastroenterol Hepatol (N Y) 2014, 10(4):219-227.
3. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98(9):2042-2047.
4. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
5. Seefe L.B. Introduction: the burden of hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S1-S4.
6. Wong R.J., Cheung R., Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014, 59(6):2188-2195.
7. Welzel T.M., Graubard B.I., Quraishi S., et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013, 108(8):1314-1321.
8. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. NEngl J Med 2003, 348(17):1625-1638.
9. Moller H., Mellemgaard A., Lindvig K., et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994, 30A(3):344-350.
10. Wolk A., Gridley G., Svensson M., et al. Aprospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001, 12(1):13-21.
11. Oh S.W., Yoon Y.S., Shin S.A. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. JClin Oncol 2005, 23(21):4742-4754.
12. Larsson S.C., Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007, 97(7):1005-1008.
13. Ohki T., Tateishi R., Shiina S., et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009, 58(6):839-844.
14. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008, 28(4):339-350.
15. Adami H.O., Chow W.H., Nyren O., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. JNatl Cancer Inst 1996, 88(20):1472-1477.
16. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126(2):460-468.
17. Wideroff L., Gridley G., Mellemkjaer L., et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. JNatl Cancer Inst 1997, 89(18):1360-1365.
18. Yang W.S., Va P., Bray F., et al. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One 2011, 6(12):e27326.
19. Wang W.M., Xu Y., Yang X.R., et al. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis. Hepatobiliary Pancreat Dis Int 2011, 10(4):346-355.
20. Wang Y.G., Wang P., Wang B., et al. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2014, 9(5):e95485.
21. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37(5):1202-1219.
22. Ratziu V., Bonyhay L., Di Martino V., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002, 35(6):1485-1493.
23. Siegel A.B., Zhu A.X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115(24):5651-5661.
24. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
25. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7(2):234-238.
26. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129(1):113-121.
27. Sanyal A., Poklepovic A., Moyneur E., et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010, 26(9):2183-2191.
28. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51(6):1972-1978.
29. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54(4):1208-1216.
30. Zen Y., Katayanagi K., Tsuneyama K., et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001, 51(2):127-131.
31. Orikasa H., Ohyama R., Tsuka N., et al. Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. JSubmicrosc Cytol Pathol 2001, 33(1-2):195-200.
32. Bencheqroun R., Duvoux C., Luciani A., et al. Hepatocellular carcinoma without cirrhosis in a patient with nonalcoholic steatohepatitis. Gastroenterol Clin Biol 2004, 28(5):497-499.
33. Bullock R.E., Zaitoun A.M., Aithal G.P., et al. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. JHepatol 2004, 41(4):685-686.
34. Gonzalez L., Blanc J.F., Sa Cunha A., et al. Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient. Semin Liver Dis 2004, 24(4):415-419.
35. Cuadrado A., Orive A., Garcia-Suarez C., et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 2005, 15(3):442-446.
36. Sato K., Ueda Y., Ueno K., et al. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch 2005, 447(6):996-999.
37. Hai S., Kubo S., Shuto T., et al. Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases. Surg Today 2006, 36(4):390-394.
38. Ichikawa T., Yanagi K., Motoyoshi Y., et al. Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis. JGastroenterol Hepatol 2006, 21(12):1865-1866.
39. Hashizume H., Sato K., Takagi H., et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2007, 19(10):827-834.
40. Guzman G., Brunt E.M., Petrovic L.M., et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008, 132(11):1761-1766.
41. Chagas A.L., Kikuchi L.O., Oliveira C.P., et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?. Braz J Med Biol Res 2009, 42(10):958-962.
42. Paradis V., Zalinski S., Chelbi E., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49(3):851-859.
43. Kawada N., Imanaka K., Kawaguchi T., et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. JGastroenterol 2009, 44(12):1190-1194.
44. Hashimoto E., Yatsuji S., Tobari M., et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. JGastroenterol 2009, 44(Suppl 19):89-95.
45. Takuma Y., Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010, 16(12):1436-1441.
46. Tokushige K., Hashimoto E., Yatsuji S., et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. JGastroenterol 2010, 45(9):960-967.
47. Yasui K., Hashimoto E., Komorizono Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9(5):428-433. [quiz: e50].
48. Wakai T., Shirai Y., Sakata J., et al. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. JGastrointest Surg 2011, 15(8):1450-1458.
49. Ikura Y., Mita E., Nakamori S. Hepatocellular carcinomas can develop in simple fatty livers in the setting of oxidative stress. Pathology 2011, 43(2):167-168.
50. Arase Y., Kobayashi M., Suzuki F., et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2012, 42(3):264-272.
51. Mittal S., Sada Y.H., El-Serag H.B., et al. Temporal trends of non-alcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015, 13(3):594-601.
52. Ertle J., Dechene A., Sowa J.P., et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011, 128(10):2436-2443.
53. Michelotti G.A., Machado M.V., Diehl A.M. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013, 10(11):656-665.
54. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109(3):433-438.
55. Harrison S.A. Liver disease in patients with diabetes mellitus. JClin Gastroenterol 2006, 40(1):68-76.
56. Balkau B., Kahn H.S., Courbon D., et al. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris prospective study. Diabetes Care 2001, 24(5):843-849.
57. Moore M.A., Park C.B., Tsuda H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev 1998, 7(2):89-107.
58. Kaburagi Y., Yamauchi T., Yamamoto-Honda R., et al. The mechanism of insulin-induced signal transduction mediated by the insulin receptor substrate family. Endocr J 1999, (46 Suppl):S25-S34.
59. Kim S.O., Park J.G., Lee Y.I. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 1996, 56(16):3831-3836.
60. Tanaka S., Mohr L., Schmidt E.V., et al. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 1997, 26(3):598-604.
61. Tanaka S., Wands J.R. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 1996, 56(15):3391-3394.
62. Saito K., Inoue S., Saito T., et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002, 51(1):100-104.
63. Peyrou M., Bourgoin L., Foti M. PTEN in liver diseases and cancer. World J Gastroenterol 2010, 16(37):4627-4633.
64. Puri P., Mirshahi F., Cheung O., et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134(2):568-576.
65. Hirosumi J., Tuncman G., Chang L., et al. Acentral role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
66. Chang Q., Zhang Y., Beezhold K.J., et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. JHepatol 2009, 50(2):323-333.
67. Hui L., Zatloukal K., Scheuch H., et al. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. JClin Invest 2008, 118(12):3943-3953.
68. Schattenberg J.M., Singh R., Wang Y., et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43(1):163-172.
69. Abdelmalek M.F., Sanderson S.O., Angulo P., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50(6):1818-1826.
70. Fujishita T., Aoki M., Taketo M.M. JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Delta716) mice. Gastroenterology 2011, 140(5):1556-1563. e6.
71. Zhou L., Huang Y., Li J., et al. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010, 27(2):255-261.
72. Rinella M.E., Siddiqui M.S., Gardikiotes K., et al. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology 2011, 54(5):1600-1609.
73. Henkel A., Green R.M. The unfolded protein response in fatty liver disease. Semin Liver Dis 2013, 33(4):321-329.
74. Dai R., Chen R., Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol 2009, 34(6):1749-1757.
75. Ozcan U., Cao Q., Yilmaz E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306(5695):457-461.
76. Xu C., Bailly-Maitre B., Reed J.C. Endoplasmic reticulum stress: cell life and death decisions. JClin Invest 2005, 115(10):2656-2664.
77. Kharroubi I., Ladriere L., Cardozo A.K., et al. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 2004, 145(11):5087-5096.
78. Vandewynckel Y.P., Laukens D., Geerts A., et al. The paradox of the unfolded protein response in cancer. Anticancer Res 2013, 33(11):4683-4694.
79. Shuda M., Kondoh N., Imazeki N., et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. JHepatol 2003, 38(5):605-614.
80. Zhang Y., Hagedorn C.H., Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta 2011, 1812(8):893-908.
81. Pikarsky E., Porat R.M., Stein I., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431(7007):461-466.
82. Hu W., Feng Z., Eveleigh J., et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002, 23(11):1781-1789.
83. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20(15):1803-1815.
84. Xu Z., Chen L., Leung L., et al. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA 2005, 102(11):4120-4125.
85. Maki A., Kono H., Gupta M., et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 2007, 14(3):1182-1190.
86. Kelesidis T., Kelesidis I., Chou S., et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010, 152(2):93-100.
87. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52(5):1836-1846.
88. Dotsch J., Rascher W., Meissner U. New insights into leptin resistance by modifying cytokine receptor signal transduction. Eur J Endocrinol 2005, 152(3):333-334.
89. Wang X.J., Yuan S.L., Lu Q., et al. Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol 2004, 10(17):2478-2481.
90. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006, 393(Pt 1):7-20.
91. Ramani K., Yang H., Xia M., et al. Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2beta. Hepatology 2008, 47(2):521-531.
92. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. JBiol Chem 2000, 275(4):2247-2250.
93. Lu S.C., Mato J.M. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev 2012, 92(4):1515-1542.
94. Mato J.M., Martinez-Chantar M.L., Lu S.C. S-adenosylmethionine metabolism and liver disease. Ann Hepatol 2013, 12(2):183-189.
95. Chen C.J., Kono H., Golenbock D., et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007, 13(7):851-856.
96. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140(6):805-820.
97. Zhang Q., Raoof M., Chen Y., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464(7285):104-107.
98. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48(1):322-335.
99. Yu L.X., Yan H.X., Liu Q., et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010, 52(4):1322-1333.
100. Dapito D.H., Mencin A., Gwak G.Y., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21(4):504-516.
101. Hosaka T., Suzuki F., Kobayashi M., et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013, 58(1):98-107.
102. Bjorkhem-Bergman L., Backheden M., Soderberg Lofdal K. Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden. Pharmacoepidemiol Drug Saf 2014, 23(10):1101-1106.
103. El-Serag H.B., Johnson M.L., Hachem C., et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009, 136(5):1601-1608.
104. Kawata S., Yamasaki E., Nagase T., et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001, 84(7):886-891.
105. Cao Z., Fan-Minogue H., Bellovin D.I., et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 2011, 71(6):2286-2297.
106. Spampanato C., De Maria S., Sarnataro M., et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol 2012, 40(4):935-941.
107. Gao J., Jia W.D., Li J.S., et al. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice. JInt Med Res 2010, 38(4):1413-1427.
108. Singh S., Singh P.P., Singh A.G., et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013, 108(6):881-891. [quiz: 892].
109. Donadon V., Balbi M., Mas M.D., et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010, 30(5):750-758.
110. Donadon V., Balbi M., Valent F., et al. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010, 16(24):3025-3032.
111. Wang P., Kang D., Cao W., et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012, 28(2):109-122.
112. Chen T.M., Lin C.C., Huang P.T., et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. JGastroenterol Hepatol 2011, 26(5):858-865.
113. Lai S.W., Chen P.C., Liao K.F., et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012, 107(1):46-52.
114. Hassan M.M., Curley S.A., Li D., et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010, 116(8):1938-1946.
115. Bhat M., Sonenberg N., Gores G.J. The mTOR pathway in hepatic malignancies. Hepatology 2013, 58(2):810-818.
116. Lu S.C., Ramani K., Ou X., et al. S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology 2009, 50(2):462-471.
117. Anstee Q.M., Day C.P. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. JHepatol 2012, 57(5):1097-1109.